SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-240399
Filing Date
2022-09-08
Accepted
2022-09-08 06:08:01
Documents
14
Period of Report
2022-09-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d359233d8k.htm   iXBRL 8-K 26073
2 EX-99.1 d359233dex991.htm EX-99.1 13751
6 GRAPHIC g359233g0908081753067.jpg GRAPHIC 2164
  Complete submission text file 0001193125-22-240399.txt   166161

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrtx-20220907.xsd EX-101.SCH 2842
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrtx-20220907_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrtx-20220907_pre.xml EX-101.PRE 10803
8 EXTRACTED XBRL INSTANCE DOCUMENT d359233d8k_htm.xml XML 3199
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 221232466
SIC: 2834 Pharmaceutical Preparations